What is VOGX's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.30B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for VOGX?

P/E (TTM) is n/a and 52-week range is $12.95 to $38.41 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s VOGX figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

Where is Vogenx, Inc. based, and what identifiers does Chartloom list?

The company context section lists headquarters in Raleigh, North Carolina, US, 14.9M shares outstanding, ISIN US92859A1060 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Vogenx, Inc.

$VOGX

Health Care · Pharmaceuticals

Run Scenarios

Overview Charts AI Summary Financials Valuation

Profile

Read AI summary

Vogenx, Inc. is a US-based company operating in Pharmaceuticals industry. The company is headquartered in Raleigh, North Carolina and currently employs 4 full-time employees. Vogenx, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for the treatment of serious diseases associated with dysfunctions in human metabolism, including post-bariatric hypoglycemia, or PBH, and gastroparesis. The firm's primary objective is to advance its lead product candidate, mizagliflozin, is an orally administered, minimally absorbed small molecule drug candidate in development for the treatment of PBH, gastroparesis, and GIP-dependent Cushing's Syndrome, or GDCS. Mizagliflozin is a selective inhibitor of SGLT1, a glucose transporter present in the gastrointestinal tract responsible for transporting dietary glucose into the bloodstream. Its VGX-2857 is a novel small molecule-based product candidate that is orally available. VGX-2857 is a combination of two novel small molecules that have demonstrated the potential to aid in weight loss in one fixed dosage form.

Employees

Website

vogenx.com

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)

EPS (TTM)

P/E (price / listing EPS)